Easy money?: Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class

International Journal of Clinical Practice

Volumn 65, Issue 3, 2011, Pages 242-244

  Pitt, B ^a   Julius, S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CANDESARTAN; GENERIC DRUG; LOSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONSTIPATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG HALF LIFE; FATIGUE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; INSULIN RESISTANCE; META ANALYSIS; MORBIDITY; MORTALITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; LOSARTAN; MALE; TETRAZOLES;

EID: 79951642081     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02642.x     Document Type: Review

References (9)

1. Grosso AM, Bodalia PN, MacAllister RJ, Hingorani AD, Moon JC, Scott MA,. Comparative clinical and cost effectiveness of candesartan and losartan in the management of hypertension and hear failure: a systematic review, meta-and cost utility analysis. Int J Clin Pract 2011; 65: 253-63. doi
2. Staessen J, Gasowski J, Wang JG, et al. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 2001; 385: 1305-15. (Pubitemid 33016494)
3. Staessen JA, Kuznetsova T, Stolarz K,. Hypertension prevalence and stroke mortality across populations. JAMA 2003; 289: 2420-2. (Pubitemid 37430177)
4. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-31. (Pubitemid 38781102)
5. Granger CB, McMurray J, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6. (Pubitemid 37093917)
6. McMurray J, Osttergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic heart function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-71. (Pubitemid 37093916)
7. Pitt B, Poole Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients symptomatic heart failure: randomized trial of the Losartan Heart Failure Study ELITE II. Lancet 2000; 355: 1582-7. (Pubitemid 30240502)
8. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high dose versus low dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double blind trial. Lancet 2009; 374: 1840-8.
9. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there a truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41: 31-6. (Pubitemid 36056788)